Morgan Stanley Renovo Rx, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.51 - $5.25 $381 - $798	-152 Reduced 46.34%	176 $0
Q4 2022 Feb 14, 2023	SELL	$1.65 - $2.35 $165 - $235	-100 Reduced 23.36%	328 $0
Q3 2022 Nov 14, 2022	SELL	$1.84 - $2.79 $2,208 - $3,348	-1,200 Reduced 73.71%	428 $1,000
Q2 2022 Oct 27, 2022	SELL	$1.52 - $2.99 $3,380 - $6,649	-2,224 Reduced 57.74%	1,628 $3,000
Q2 2022 Aug 15, 2022	SELL	$1.52 - $2.99 $3,380 - $6,649	-2,224 Reduced 57.74%	1,628 $3,000
Q1 2022 Oct 27, 2022	BUY	$2.87 - $4.9 $6,382 - $10,897	2,224 Added 136.61%	3,852 $11,000
Q1 2022 May 13, 2022	BUY	$2.87 - $4.9 $11,055 - $18,874	3,852 New	3,852 $11,000

2.87M

Ticker RNXT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,066,860
Market Cap $10.6M
Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.